ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 2032 • ACR Convergence 2023

    Goal Concordance in Rheumatoid Arthritis Patients with Depression – What Do Patients Prioritize?

    Allison Schue1, Rachel Matsumoto2 and Jennifer Barton3, 1Providence St. Vincent Medical Center, Portland, OR, 2VA Portland Health Care System, Portland, OR, 3VA Portland Health Care System/OHSU, Portland, OR

    Background/Purpose: Depression prevalence in patients with rheumatoid arthritis (RA) is higher than the general population (~40% and 4.1%, respectively). Patients with depressive symptoms show reduced…
  • Abstract Number: 2108 • ACR Convergence 2023

    Specific Symptom Clusters at Diagnosis Signal a Poorer Early RA Prognosis: Data from the Canadian Early Arthritis Cohort (CATCH)

    Susan Bartlett1, Clifton Bingham2, Orit Schieir3, Marie-France Valois4, Janet Pope5, Louis Bessette6, Gilles Boire7, Carol Hitchon8, Edward Keystone9, Carter Thorne10, Diane Tin11, Glen Hazlewood12 and Vivian Bykerk13, 1McGill University, Montreal, QC, Canada, 2Johns Hopkins Medicine, Baltimore, MD, 3McGill University, Montréal, QC, Canada, 4McGill University, Pointe-Claire, QC, Canada, 5University of Western Ontario, London, ON, Canada, 6Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec City, QC, Canada, 7Université de Sherbrooke, Sherbrooke, QC, Canada, 8University of Manitoba, Winnipeg, MB, Canada, 9Keystone Consulting Enterprises Inc., Toronto, ON, Canada, 10Southlake Regional Health Centre, Newmarket, ON, Canada, 11Newmarket Rheumatology Consultants, Newmarket, ON, Canada, 12University of Calgary, Calgary, AB, Canada, 13Hospital for Special Surgery, New York, NY

    Background/Purpose: Symptom clusters are stable groups of 2+ symptoms that are related to each other and frequently co-occur. Identifying symptom clusters in early RA may…
  • Abstract Number: 2124 • ACR Convergence 2023

    Expansion of Atypical B Cells Accompanies Rheumatoid Arthritis-like Immune Dysregulation in ACPA+ At-risk Individuals

    Adam Savage1, Ziyuan He1, Marla Glass1, Julian Reading1, LauraKay Moss2, Marie Feser2, Vlad Tsaltskan3, Katherine Nguyen Nguyen3, Kristen Demoruelle2, kristine Kuhn4, David Boyle3, Cate Speake5, Xiao-Jun Li1, Peter Skene1, Troy Torgerson1, Tom Bumol1, V. Michael Holers6, Jane Buckner7, Gary Firestein8, kevin Deane2 and Mark Gillespie1, 1Allen Institute for Immunology, Seattle, WA, 2University of Colorado Anschutz Medical Campus, Aurora, CO, 3University of California San Diego, La Jolla, CA, 4University of Colorado School of Medicine, Aurora, CO, 5Benaroya Research Institute, Seattle, WA, 6University of Colorado, Denver, CO, 7Benaroya Research Institute at Virginia Mason, Seattle, WA, 8University of California San Diego, San Diego, CA

    Background/Purpose: Seropositive RA is preceded by an at-risk stage characterized by elevated circulating autoantibodies (AAb), including ACPA, in otherwise healthy individuals without clinically-apparent inflammatory arthritis.…
  • Abstract Number: 2140 • ACR Convergence 2023

    Serum Alarmins and the Risk of Interstitial Lung Disease in Patients with Rheumatoid Arthritis

    Ted R Mikuls1, Bryant England2, Harlan Sayles2, Tate Johnson2, Michael Duryee2, Carlos Hunter2, Joshua Baker3, Gail Kerr4, Gary Kunkel5, Grant Cannon6, Brian Sauer7, K Wysham8, Amy Joseph9, Beth Wallace10, Geoffrey Thiele2 and Jill Poole2, 1Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, 2University of Nebraska Medical Center, Omaha, NE, 3University of Pennsylvania, Philadelphia, PA, 4Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 5University of Utah, Salt Lake City, UT, 6University of Utah and Salt Lake City VA, Salt Lake City, UT, 7Salt Lake City VA/University of Utah, Salt Lake City, UT, 8VA Puget Sound/University of Washington, Seattle, WA, 9Washington University / St. Louis VA, St. Louis, MO, 10Ann Arbor VA, Ann Arbor, MI

    Background/Purpose: Alarmins are proteins found in the nuclei of epithelial, endothelial, and immune cells that are released following cell damage and act as stress signals.…
  • Abstract Number: 2156 • ACR Convergence 2023

    Efficacy of Olokizumab in Comorbid Depressive Disorder in Patients with Rheumatoid Arthritis: Preliminary Results of a Study

    Vibeke Strand1, Tatiana Lisitsyna2, Anton Abramkin2, Dmitry Veltishchev3, Olga Seravina3, Oksana Kovalevskaya3, Anastasia Borisova4, Sofia Kuzkina5, Vasily Ignatiev5 and EVGENY NASONOV6, 1Stanford University, Portola Valley, CA, 2V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, 3Moscow Research Institute of Psychiatry branch of Serbsky National Medical Research Center for Psychiatry and Narcology of the Ministry of Health, Moscow, Russia, 4Moscow Research Institute of Psychiatry branch of Serbsky National Medical Research Center for Psychiatry and Narcology of the Ministry of Health, Mosocw, Russia, 5R-Pharm, Moscow, Russia, 6Scientific Research Institute of Rheumatology, Moscow, Russia

    Background/Purpose: Interleukin-6 (IL) plays an important role in the pathogenesis of comorbid rheumatoid arthritis (RA) depression, and IL-6 inhibitors used to treat RA patients may…
  • Abstract Number: 2173 • ACR Convergence 2023

    Window of Opportunity in the Treatment of Rheumatoid Arthritis-Interstitial Lung Disease with Abatacept. National Multicenter Study of 509 Patients

    Ana Serrano-Combarro1, Belén Atienza-Mateo2, libe Ibarrola-Paino3, Ivette Casafont-Sole4, Rafael Benito Melero-Gonzalez5, Alba Perez Linaza6, Santos Castañeda7, Rafaela Ortega Castro8, Natalia Mena Vazquez9, Nuria Vegas Revenga10, Lucia Cristina Dominguez Casas11, Cilia Peralta12, Trinidad Pérez-Sandoval13, Lorena Perez-Albadalejo14, Ruben Lopez-Sanchez15, MARIA GUADALUPE MANZANO CANABAL16, Anahy Maria Brandy-Garcia17, Patricia Lopez-Viejo18, Gema Bonilla19, Olga Maiz-Alonso20, Carmen carrasco-Cubero21, Marta Garijo Bufort22, Mireia Moreno23, Ana Urruticoechea24, Sergio Ordonez-Palau25, Carmen Gonzalez-Montagut Gomez26, andrea Garcia-Valle27, Juan Ramon De Dios Jimenez De Aber28, Fernando Lozano29, Tomás Vazquez-Rodriguez30, Maria Martin-Lopez31, Juan Maria Blanco-Madrigal32, Delia Fernández-Lozano33, Ignacio Brana Abascal34, Jesus Loarce-Martos35, Emilio Giner-Serret36, Virginia Ruiz-Esquide37, Clara ventin-Rodriguez38, Marina Rodriguez-lopez39, Pablo Andujar-Brazal40, Julia Fernandez-Melon41, Lilian Maria Lopez42, carlos Fernandez-Diaz43, Javier Loricera44, Ivan Ferraz Amaro45, Diego Ferrer46, Ricardo Blanco47 and On behalf of the Collaborative Group Members48, 1Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain, 2Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 3Hospital Universitario de Navarra, Pamplona, Spain, 4Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 5CHU Vigo, O Carballino, Spain, 6SERV. REUMATOLOGIA, Cadiz, Spain, 7Hospital Universitario de la Princesa, Madrid, Spain, 8Hospital Reina Sofía, Cordoba, Spain, 9IBIMA, Málaga, Spain, 10Hospital Galdakao- Usansolo, Galdakao, Spain, 11Hospital Universtario San Agustin, Oviedo, Spain, 12Hospital Clínico Lozano Blesa, Zaragoza, Spain, 13Hospital de León, León, Spain, 14Division of Rheumatology, Hospital Universitario de Jaén, Jaén, Spain, 15Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain, 16CAZA, Salamanca, Spain, 17Hospital Germans Trias i Pujol, Badalona, Spain, 18Division of Rheumatology, Hospital Severo Ochoa, Leganéz, Spain, 19Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, 20University Hospital Donostia, San Sebastian, Spain, 21Department of Rheumatology, Hospital Universitario de Badajoz, Badajoz, Spain, 22Hospital de Sagunto, Valencia, Spain, 23Parc Tauli Hospital Universitari, I3PT(UAB), Barcelona, Spain, 24Hospital Can Misses, Ibiza, Spain, 25H. Arnau de Vilanova, Lleida, Spain, 26H. Clínico Universitario de Valladolid, Valladolid, Spain, 27Division of Rheumatology, Complejo Asistencial Universitario de Palencia, Palencia, Spain, 28Hospital de Araba, Alava, Spain, 29Hospital Universitario 12 de Octubre, Madrid, Spain, 30Rheumatology, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain, 31Hospital 12 de Octubre, Madrid, Spain, 32Division of Rheumatology, H. Universitario de Basurto, Bilbao, Spain, 33Hospital de Mérida, Merida, Spain, 34Division of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, 35Ramón y Cajal University Hospital, Madrid, Spain, 36Hospital Royo Villanova, Teruel, Spain, 37Hospital Clinic, Rheumatology, Barcelona, Spain, 38Division of Rheumatology, Hospital Universitario de A Coruña, A Coruña, Spain, 39Division of Rheumatology, Hospital Clínico Universitario de Santiago, La Coruna, Spain, 40Division of Rheumatology, Hospital Universitario Doctor Peset, Valencia, Spain, 41Division of Rheumatology, Hospital Universitario Son Espases, Palma de Mallorca, Spain, 42Division of Rheumatology, Hospital Universitario Son Llàtzer, Mallorca, Spain, 43Division of Rheumatology, Hospital Universitario Reina Sofía, Murcia, Spain, 44Hospital Universitario Marqués de Valdecilla, Santander, Spain, 45Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 46Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 47Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 48Spanish Collaborative Group of Interstitial Lung Disease Associated with Rheumatoid Arthritis, Spain, Spain

    Background/Purpose: Interstitial lung disease (ILD) is a severe complication of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated efficacy in the treatment of RA-ILD, especially if…
  • Abstract Number: 2455 • ACR Convergence 2023

    Addressing Native American Health Disparities in Rheumatoid Arthritis by Training Primary Care Providers: Expanding the Reach of the RAE Initiative

    Jennifer Mandal1, Zara Izadi1, Tabitha Carroway1, Gwendolyn Grant2, Mary Margaretten1 and Jinoos Yazdany1, 1University of California San Francisco, San Francisco, CA, 2Centura Health, Durango, CO

    Background/Purpose: The United States faces a critical shortage of rheumatology providers. This shortage is especially dire in rural areas, such as Navajo Nation, where primary…
  • Abstract Number: 2543 • ACR Convergence 2023

    Clinical and Radiographic Results of Tapering and Withdrawing CsDMARDs versus Stable Treatment in Patients with Rheumatoid Arthritis in Remission: 3-year Results from a Randomized Controlled Trial

    Kaja Eriksrud Kjørholt1, Nina Paulshus Sundlisæter1, Anna-Birgitte Aga1, Joseph Sexton1, Inge Olsen2, Hallvard Fremstad3, Cristina Spada4, Tor Magne Madland5, Christian A Høili6, Gunnstein Bakland7, Åse Lexberg8, Inger Johanne Widding Hansen9, Inger Myrnes Hansen10, Hilde Haukland11, Maud-Kristine Aga Ljoså12, Ellen Moholt1, Till Uhlig1, Tore Kvien1, Daniel Solomon13, Désirée van der Heijde14, Espen Haavardsholm1 and Siri Lillegraven1, 1Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, 2Oslo University Hospital, Oslo, Norway, 3Møre og Romsdal Hospital Trust, Ålesund, Norway, 4Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, 5Haukeland University Hospital, Bergen, Norway, 6Østfold Hospital Trust, Moss, Norway, 7University Hospital of North Norway, Tromsø, Norway, 8Drammen Hospital, Vestre Viken HF, Drammen, Norway, 9Sørlandet Hospital HF, Kristiansand, Norway, 10Helgeland Hospital Trust Mo i Rana, Mo i Rana, Norway, 11Martina Hansens Hospital, Bærum, Norway, 12Ålesund Hospital, Ålesund, Norway, 13Brigham and Women's Hospital, Newton, MA, 14Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Tapering of disease-modifying antirheumatic drugs (DMARDs) to achieve drug-free remission is a potential goal for the growing group of patients with rheumatoid arthritis (RA)…
  • Abstract Number: 0045 • ACR Convergence 2023

    Discovery and Characterization of a Selective, Orally Bioavailable PAD4 Inhibitor to Target NETs Driven Autoimmune and Inflammatory Diseases

    Min Yang1, song feng1, yuling wen1, Xiaoming ren1, Huijuan Li1, lili yao1, Zhi xie2 and Wenge zhong1, 1Regor Therapeutics, Shanghai, China, 2Regor Pharmaceuticals, Inc., San Francisco, CA

    Background/Purpose: Protein arginine deiminases (PAD) 4 is an enzyme that catalyzes the conversion of protein-embedded arginine to citrulline. It is essential for neutrophil extracellular traps…
  • Abstract Number: 0122 • ACR Convergence 2023

    Depression, Anxiety and Post-Traumatic Stress Disorder in Association with Cardiovascular Disease Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis in the All of Us Research Program

    Jeong Yee1, Emily G. Oakes1, May Choi2, Candace Feldman1, Elizabeth Karlson1 and Karen Costenbader3, 1Brigham and Women's Hospital, Boston, MA, 2University of Calgary, Calgary, AB, Canada, 3Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Cardiovascular disease (CVD) risk is increased for patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Mental health conditions such as depression, anxiety,…
  • Abstract Number: 0277 • ACR Convergence 2023

    Anti-carbamylated Antibodies in Autoimmunity – Focus on Their Diagnostic and Prognostic Value: A Systematic Review and Meta-analysis

    Julie Sarrand, Dorian Parisis, Muhammad Soyfoo and Paschalis Sidiras, Erasmus Hospital, Brussels, Belgium

    Background/Purpose: This is the first systematic review and meta-analysis to examine the prevalence, the diagnostic and the prognostic value of anti-carbamylated protein (CarP) antibodies in…
  • Abstract Number: 0389 • ACR Convergence 2023

    The Role of anti-CCP3 Antibodies in anti-CCP2 Antibody Negative Patients with Musculoskeletal Symptoms

    Andrea Di Matteo1, Kulveer Mankia2, Leticia Garcia-Montoya2, Jacqueline Nam2, Sana sharrack3, Michael Mahler4 and Paul Emery3, 1Polytechnic University of Marche, Jesi, Italy, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 4Werfen, San Diego, CA

    Background/Purpose: To investigate, in primary care, whether testing anti-CCP3 antibodies in anti-CCP2 negative individuals with musculoskeletal (MSK) symptoms, improved the prediction of inflammatory arthritis (IA)/rheumatoid…
  • Abstract Number: 0406 • ACR Convergence 2023

    Obesity Is a Risk Factor for Poor Response to Treatment in Early Rheumatoid Arthritis – a NORD-STAR Spin-Off Study

    Violetta Dubovyk1, Gerdur Maria Grondal2, Bjorn Gudbjornsson3, Espen A Haavardsholm4, Marte Schrumpf Heiberg4, Merete Hetland5, Kim Hørslev-Petersen6, Meliha Kapetanovic7, Alf Kastbom8, John Lampa9, Kristina Lend10, Dan Nordstrom11, Michael Nurmohamed12, Milad Rizk13, Annika Söderbergh14, Till Uhlig15, Mikkel Østergaard16, Ronald van Vollenhoven12, Anna Rudin17 and Cristina Maglio18, 1University of Gothenburg, Gothenburg, Sweden, 2Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, 3Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, 4Diakonhjemmet Hospital, Oslo, Norway, 5Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, 6University of Southern Denmark, Odense, Denmark, 7Lund University and Skåne University Hospital, Lund, Sweden, 8Linköping University, Linköping, Sweden, 9Stockholm County, Hãsselby, Sweden, 10Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, 11Helsinki University Hospital, Helsinki, Finland, 12Amsterdam University Medical Centers, Amsterdam, Netherlands, 13Västmanlands Hospital Västerås, Västerås, Sweden, 14Örebro University Hospital, Örebro, Sweden, 15Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, 16Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, 17Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 18Institute of Medicine, University of Gothenburg, Gothenburg, Sweden

    Background/Purpose: Several therapeutic options are currently available to treat rheumatoid arthritis (RA); however, the response to treatment is highly variable, and not all patients achieve…
  • Abstract Number: 0422 • ACR Convergence 2023

    Electronic Health Record-Based Machine Learning Model for Predicting Disease Activity in Patients with Rheumatoid Arthritis

    Zelin Yun1, Chun Li2 and Zhanguo Li2, 1Peking University People's Hospital, Beijing, China, 2Peking University People’s Hospital, Beijing, China

    Background/Purpose: Rheumatoid arthritis (RA) is one of the most prevalent chronic inflammatory diseases in which synovitis gradually leads to polyarthritis and joint destruction. Poor response…
  • Abstract Number: 0439 • ACR Convergence 2023

    Humoral Immune Response to 13 Valent-conjugate and 23-valent Polysaccharide Pneumococcal Vaccines in RA Patients Treated with Abatacept: Results of the Open Randomized Controlled Trial VACINA (Vaccination Against Pneumococcal in Naïve Abatacept Rheumatoid Arthritis Patients)

    JACQUES MOREL1, Olivier Brocq2, Cécile Gaujoux Viala3, Arnaud Constantin4, Slim Lassoued5, Emanuelle Dernis6, Christophe Richez7, Cedric Lukas8, Claire Daien9 and Claire Duflos10, 1Protocole thérapeutique immuno-rhumatologie, Montpellier, France, 2Hospital of Princesse Grâce de Monaco, Monaco, Monaco, 3IDESP Univ Montpellier, INSERM, Rheumatology, CHU Nîmes, Montpellier, France, 4Teaching hospital Purpan, and University of Paul Sabatier, Toulouse, France, 5Hospital of Jean-Rougié, Cahors, France, 6CH Le Mans, Le Mans, France, 7Université de Bordeaux, Bordeaux, France, 8CHU Montpellier, Montpellier, France, 9University Hospital, Montpellier, France, 10CHU and University of Montpellier, Montpellier, France

    Background/Purpose: To prevent infections, EULAR recommends to vaccinate RA patients against streptococcal pneumoniae. PCV13 is a T- cell dependent vaccine whereas PPSV23 induces a T-independent…
  • « Previous Page
  • 1
  • …
  • 52
  • 53
  • 54
  • 55
  • 56
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology